Skip to content 
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. more
| Time Frame | KRYS | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -7.96% | -3.93% | -0.67% |
| 1-Month Return | -6.98% | -2.41% | -1.33% |
| 3-Month Return | 8.39% | 1.64% | -0.29% |
| 6-Month Return | 74.72% | 11.65% | 5.08% |
| 1-Year Return | 41.78% | 3.11% | 19.01% |
| 3-Year Return | 229.85% | 19.21% | 68.62% |
| 5-Year Return | 261.9% | 36.52% | 78.6% |
| 10-Year Return | 2284.3% | 126.5% | 240.69% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | 50.70M | 290.51M | 389.13M | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":13.03,"profit":true},{"date":"2024-12-31","value":74.66,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Cost of Revenue | 2.77M | 4.05M | 3.09M | 20.06M | 28.77M | [{"date":"2021-12-31","value":9.62,"profit":true},{"date":"2022-12-31","value":14.09,"profit":true},{"date":"2023-12-31","value":10.75,"profit":true},{"date":"2024-12-31","value":69.72,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | (2.77M) | (4.05M) | 47.60M | 270.45M | 360.36M | [{"date":"2021-12-31","value":-0.77,"profit":false},{"date":"2022-12-31","value":-1.13,"profit":false},{"date":"2023-12-31","value":13.21,"profit":true},{"date":"2024-12-31","value":75.05,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | - | - | 93.90% | 93.09% | 92.61% | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.15,"profit":true},{"date":"2025-12-31","value":98.62,"profit":true}] |
| Operating Expenses | 68.28M | 145.20M | 157.33M | 204.76M | 199.06M | [{"date":"2021-12-31","value":33.34,"profit":true},{"date":"2022-12-31","value":70.91,"profit":true},{"date":"2023-12-31","value":76.84,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":97.22,"profit":true}] |
| Operating Income | (68.28M) | (145.20M) | (109.73M) | 65.69M | 161.29M | [{"date":"2021-12-31","value":-42.33,"profit":false},{"date":"2022-12-31","value":-90.02,"profit":false},{"date":"2023-12-31","value":-68.03,"profit":false},{"date":"2024-12-31","value":40.73,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (2.59M) | 10.44M | 145.25M | 59.32M | 56.35M | [{"date":"2021-12-31","value":-1.78,"profit":false},{"date":"2022-12-31","value":7.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":40.84,"profit":true},{"date":"2025-12-31","value":38.8,"profit":true}] |
| Pre-Tax Income | (69.57M) | (139.97M) | 12.90M | 95.36M | 189.47M | [{"date":"2021-12-31","value":-36.72,"profit":false},{"date":"2022-12-31","value":-73.88,"profit":false},{"date":"2023-12-31","value":6.81,"profit":true},{"date":"2024-12-31","value":50.33,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income Taxes | 2.73M | 34.05M | 1.97M | 6.20M | (15.36M) | [{"date":"2021-12-31","value":8.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":5.77,"profit":true},{"date":"2024-12-31","value":18.2,"profit":true},{"date":"2025-12-31","value":-45.11,"profit":false}] |
| Income After Taxes | (72.30M) | (174.02M) | 10.93M | 89.16M | 204.83M | [{"date":"2021-12-31","value":-35.3,"profit":false},{"date":"2022-12-31","value":-84.96,"profit":false},{"date":"2023-12-31","value":5.34,"profit":true},{"date":"2024-12-31","value":43.53,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income From Continuous Operations | (69.57M) | (139.97M) | 10.93M | 89.16M | 204.83M | [{"date":"2021-12-31","value":-33.96,"profit":false},{"date":"2022-12-31","value":-68.34,"profit":false},{"date":"2023-12-31","value":5.34,"profit":true},{"date":"2024-12-31","value":43.53,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (69.57M) | (139.97M) | 10.93M | 89.16M | 204.83M | [{"date":"2021-12-31","value":-33.96,"profit":false},{"date":"2022-12-31","value":-68.34,"profit":false},{"date":"2023-12-31","value":5.34,"profit":true},{"date":"2024-12-31","value":43.53,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| EPS (Diluted) | (3.06) | (4.51) | (3.40) | 3.00 | 6.85 | [{"date":"2021-12-31","value":-44.7,"profit":false},{"date":"2022-12-31","value":-65.88,"profit":false},{"date":"2023-12-31","value":-49.66,"profit":false},{"date":"2024-12-31","value":43.82,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| KRYS | |
|---|---|
| Cash Ratio | 8.04 |
| Current Ratio | 9.95 |
| Quick Ratio | 9.56 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| KRYS | |
|---|---|
| ROA (LTM) | 8.44% |
| ROE (LTM) | 18.91% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| KRYS | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| KRYS | |
|---|---|
| Trailing PE | 38.06 |
| Forward PE | 45.87 |
| P/S (TTM) | 19.56 |
| P/B | 6.35 |
| Price/FCF | 101 |
| EV/R | 17.80 |
| EV/Ebitda | 41.28 |
Krystal Biotech Inc (KRYS) share price today is $253.69
Yes, Indians can buy shares of Krystal Biotech Inc (KRYS) on Vested. To buy
Yes, you can purchase fractional shares of Krystal Biotech Inc (KRYS) via the Vested app. You can start investing in Krystal Biotech Inc (KRYS) with a minimum investment of $1.
You can invest in shares of Krystal Biotech Inc (KRYS) via Vested in three simple steps:
The 52-week high price of Krystal Biotech Inc (KRYS) is $298.3. The 52-week low price of Krystal Biotech Inc (KRYS) is $122.8.
The price-to-earnings (P/E) ratio of Krystal Biotech Inc (KRYS) is 38.0599
The price-to-book (P/B) ratio of Krystal Biotech Inc (KRYS) is 6.35
The dividend yield of Krystal Biotech Inc (KRYS) is 0.00%
The market capitalization of Krystal Biotech Inc (KRYS) is $7.61B
The stock symbol (or ticker) of Krystal Biotech Inc is KRYS
Consider the share price of Krystal Biotech Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Krystal Biotech Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Krystal Biotech Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Krystal Biotech Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Krystal Biotech Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Krystal Biotech Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
